drugset
Drugs / FLU-IGIV
last change Jun 2019 re-read 3 minutes ago

FLU-IGIV

Protein / enzyme biologic

Developed for
swine influenza
Investigated by
Emergent BioSolutions

Trials 1

today NCT03315104 · Ph 2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03315104 Nov 2017 → Jun 2019 swine influenza Emergent BioSolutions Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2018-01-04 Emergent BioSolutions Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection emergentbiosolutions.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FLU-IGIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315104 ↗
Modality Protein / enzyme biologic “The study drug that contains antibodies against the flu is called anti-influenza immunoglobulin intravenous (FLU-IGIV).” NCT03315104 ↗
Route Intravenous “Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline.” NCT03315104 ↗